139181-28-5

Basic information

• Product Name: [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-(methylsulfonyl)-
• CAS NO: 139181-28-5
• Molecular Formula: C9H8N6O3S
• Molecular Weight: 280.267
• Mol File: 139181-28-5.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-(methylsulfonyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-(methylsulfonyl)-(139181-28-5)
• EPA Substance Registry System: [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-(methylsulfonyl)-(139181-28-5)

Safety Data

• Hazardous Substances Data: 139181-28-5(Hazardous Substances Data)

Usage

General Description

The chemical [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-(methylsulfonyl)- is a compound with the molecular formula C9H9N5O2S. It is an organic compound that contains a triazolo-triazinamine core with a furanyl and methylsulfonyl functional group. [1,2,4]Triazolo[1,5-a][1,3,5]triazin-7-amine, 2-(2-furanyl)-5-(methylsulfonyl)- has potential applications in pharmaceutical research and drug development due to its unique structure and potential biological activity. It may also have potential uses in the development of new materials or as a building block for more complex chemical compounds. Further research is needed to fully understand the properties and potential applications of this compound.

Upstream product

• 6053-32-3 N-(furan-2-ylcarbonyl)carbonohydrazonic diamide 
• 3663-61-4 3-Amino-5-(furan-2-yl)-1H-1,2,4-triazole 
• 3326-71-4 2-furoic acid hydrazide 
• 64741-01-1 m-chloroperoxybenzoic acid 
• 139181-27-4 LUF₅₄₄₃ 
• 114953-87-6 5-furan-2-yl-3-methyl-1H-[1,2,4]triazole 
• 611-13-2 2-furoic acid methyl ester 
• 617-90-3 2-furancarbonitrile 
• 3663-61-4 5-(furan-2-yl)-2H-1,2,4-triazol-3-amine 

Downstream Products

• 1436428-60-2 ethyl 4-(4-(2-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5-yl)amino)ethyl)-phenoxy)butanoate 
• 1436428-61-3 ethyl 4-((2-(furan-2-yl)-5-((4-hydroxyphenethyl)amino)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-yl)amino)butanoate 
• 1436428-62-4 ethyl 4-((5-((4-(4-ethoxy-4-oxobutoxy)phenethyl)amino)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-yl)amino)butanoate 
• 1436428-63-5 4-(2-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5yl)amino)ethyl)phenyl acetate 
• 1436428-64-6 4-(2-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5yl)amino)ethyl)phenyl butyrate 
• 1436428-65-7 4-(2-((7-amino-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazin-5yl)amino)ethyl)phenyl decanoate 
• 1436428-24-8 N⁵-(4-bromophenethyl)-2-(furan-2-yl)-[1,2,4]triazolo[1,5-a][1,3,5]triazine-5,7-diamine 
• 139179-64-9 2-(furan-2-yl)-5-phenethoxy-[1,2,4]triazolo[1,5-a][1,3,5]triazin-7-amine 

Relevant articles and documents

NON BRAIN PENETRANT A2A INHIBITORS AND METHODS FOR USE IN THE TREATMENT OF CANCERS

The present invention relates to compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention further relates to the use of the compounds of Formula (I) as A2A inhibitors. The invention also relates to the use of the compounds of F

TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS

The present invention provides triazolotriazine derivatives of formula (1) as A2A receptor antagonists. Compounds of formula (1) and pharmaceutical compositions including the compounds can be used for the treatment of disorders related to A2A receptor hyp

Synthesis and pharmacological evaluation of dual acting ligands targeting the adenosine A2A and dopamine D2 receptors for the potential treatment of parkinsons disease

A relatively new strategy in drug discovery is the development of dual acting ligands. These molecules are potentially able to interact at two orthosteric binding sites of a heterodimer simultaneously, possibly resulting in enhanced subtype selectivity, higher affinity, enhanced or modified physiological response, and reduced reliance on multiple drug administration regimens. In this study, we have successfully synthesized a series of classical heterobivalent ligands as well as a series of more integrated and drug-like dual acting molecules, incorporating ropinirole as a dopamine D2 receptor agonist and ZM 241385 as an adenosine A2A receptor antagonist. The best compounds of our series maintained the potency of the original pharmacophores at both receptors (adenosine A2A and dopamine D2). In addition, the integrated dual acting ligands also showed promising results in preliminary blood-brain barrier permeability tests, whereas the classical heterobivalent ligands are potentially more suited as pharmacological tools.